You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSulfisoxazole
Accession NumberDB00263  (APRD00595)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. [PubChem]

Structure
Thumb
Synonyms
3,4-Dimethyl-5-sulfanilamidoisoxazole
3,4-Dimethyl-5-sulfonamidoisoxazole
3,4-Dimethyl-5-sulphanilamidoisoxazole
3,4-Dimethyl-5-sulphonamidoisoxazole
3,4-Dimethylisoxazole-5-sulfanilamide
3,4-Dimethylisoxazole-5-sulphanilamide
4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulfonamide
4-Amino-N-(3,4-dimethyl-5-isoxazolyl)benzenesulphonamide
5-(4-Aminophenylsulfonamido)-3,4-dimethylisoxazole
5-(P-Aminobenzenesulfonamido)-3,4-dimethylisoxazole
5-(P-Aminobenzenesulphonamido)-3,4-dimethylisoxazole
5-Sulfanilamido-3,4-dimethylisoxazole
5-Sulphanilamido-3,4-dimethyl-isoxazole
N'-(3,4)dimethylisoxazol-5-yl-sulphanilamide
N(1)-(3,4-Dimethyl-5-isoxazolyl)sulfanilamide
N(1)-(3,4-Dimethyl-5-isoxazolyl)sulphanilamide
Sulfadimethylisoxazole
Sulfafurazol
Sulfafurazole
Sulfafurazolum
Sulfaisoxazole
Sulfasoxazole
Sulfisonazole
Sulfisoxasole
Sulfisoxazol
Sulfofurazole
Sulphadimethylisoxazole
Sulphafurazol
Sulphafurazole
Sulphaisoxazole
Sulphisoxazol
Sulphofurazole
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Novo-soxazole 500mgtablet500 mgoralNovopharm Limited1967-12-312005-08-10Canada
Sulfisoxazole 500mg Tabletstablet500 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Sulfizole Tab 500mgtablet500 mgoralIcn Canada Ltd.1963-12-312005-04-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Sulfisoxazole Tab 500mgtablet500 mgoralApotex Inc1977-12-31Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
GantrisinRoche
NeoxazolNot Available
Brand mixtures
NameLabellerIngredients
Erythromycin Ethylsuccinate and Sulfisoxazole AcetylRebel Distributors Corp
PediazoleAmdipharm Limited
Salts
Name/CASStructureProperties
Acetyl sulfisoxazole
ThumbNot applicableDBSALT000856
Sulfisoxazole diolamine
ThumbNot applicableDBSALT001376
Categories
UNII740T4C525W
CAS number127-69-5
WeightAverage: 267.304
Monoisotopic: 267.067761987
Chemical FormulaC11H13N3O3S
InChI KeyInChIKey=NHUHCSRWZMLRLA-UHFFFAOYSA-N
InChI
InChI=1S/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3
IUPAC Name
4-amino-N-(dimethyl-1,2-oxazol-5-yl)benzene-1-sulfonamide
SMILES
CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzenesulfonamides
Direct ParentAminobenzenesulfonamides
Alternative Parents
Substituents
  • Aminobenzenesulfonamide
  • Sulfonylaniline
  • Substituted aniline
  • Aniline
  • Primary aromatic amine
  • Heteroaromatic compound
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Oxazole
  • Isoxazole
  • Azole
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Primary amine
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of severe, repeated, or long-lasting urinary tract infections, meningococcal meningitis, acute otitis media, trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis, malaria and other bacterial infections.
PharmacodynamicsSulfisoxazole is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus.
Mechanism of actionSulfisoxazole is a competitive inhibitor of the enzyme dihydropteroate synthetase. It inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the pteridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase. The inhibited reaction is necessary in these organisms for the synthesis of folic acid.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationThe mean urinary excretion recovery following oral administration of sulfisoxazole is 97% within 48 hours, of which 52% is intact drug, with the remaining as the N4-acetylated metabolite. It is excreted in human milk.
Half lifeNot Available
ClearanceNot Available
ToxicityLD50=6800 mg/kg (Orally in mice)
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9908
Blood Brain Barrier+0.9382
Caco-2 permeable-0.6046
P-glycoprotein substrateNon-substrate0.8891
P-glycoprotein inhibitor INon-inhibitor0.9357
P-glycoprotein inhibitor IINon-inhibitor0.9698
Renal organic cation transporterNon-inhibitor0.9322
CYP450 2C9 substrateNon-substrate0.8056
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateNon-inhibitor0.9621
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9358
CYP450 2C19 inhibitorNon-inhibitor0.9292
CYP450 3A4 inhibitorNon-inhibitor0.9386
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8037
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7969
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.4586 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9896
hERG inhibition (predictor II)Non-inhibitor0.9442
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Hoffmann la roche inc
  • Mk laboratories inc
  • Alra laboratories inc
  • Parke davis div warner lambert co
  • Barr laboratories inc
  • Heather drug co inc
  • Impax laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Lannett co inc
  • Lederle laboratories div american cyanamid co
  • Pharmeral inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Solvay pharmaceuticals
  • Sola barnes hind
Packagers
Dosage forms
FormRouteStrength
Tabletoral500 mg
Granule, for suspensionoral
Powder for suspensionoral
Prices
Unit descriptionCostUnit
Sulfisoxazole crystals1.01USD g
Sulfazine EC 500 mg Enteric Coated Tabs0.42USD tab
Sulfazine ec 500 mg tablet0.38USD tablet
Sulfazine 500 mg tablet0.25USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point191 °CPhysProp
water solubility300 mg/L (at 37 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.01HANSCH,C ET AL. (1995)
logS-2.91ADME Research, USCD
pKa5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.313 mg/mLALOGPS
logP1.14ALOGPS
logP0.73ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)5.8ChemAxon
pKa (Strongest Basic)2.17ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area98.22 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity67.92 m3·mol-1ChemAxon
Polarizability26.93 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.71 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesJ01EB05S01AB02
AHFS Codes
  • 08:12.20
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72 KB)
Interactions
Drug Interactions
Drug
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Sulfisoxazole.
AcetohexamideAcetohexamide may increase the hypoglycemic activities of Sulfisoxazole.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Sulfisoxazole.
AlogliptinAlogliptin may increase the hypoglycemic activities of Sulfisoxazole.
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Sulfisoxazole.
AmrinoneThe metabolism of Amrinone can be decreased when combined with Sulfisoxazole.
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Sulfisoxazole.
BepridilThe metabolism of Bepridil can be decreased when combined with Sulfisoxazole.
BexaroteneThe serum concentration of Sulfisoxazole can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Bosentan can be increased when it is combined with Sulfisoxazole.
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Sulfisoxazole.
CanagliflozinCanagliflozin may increase the hypoglycemic activities of Sulfisoxazole.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Sulfisoxazole.
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Sulfisoxazole.
ChlorpropamideSulfisoxazole may increase the hypoglycemic activities of Chlorpropamide.
CitalopramSulfisoxazole may increase the QTc-prolonging activities of Citalopram.
ClindamycinThe therapeutic efficacy of Clindamycin can be decreased when used in combination with Sulfisoxazole.
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Sulfisoxazole.
DapsoneThe metabolism of Dapsone can be decreased when combined with Sulfisoxazole.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Sulfisoxazole.
DiclofenacThe serum concentration of Diclofenac can be increased when it is combined with Sulfisoxazole.
DicoumarolSulfisoxazole may increase the anticoagulant activities of Dicoumarol.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Sulfisoxazole.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Sulfisoxazole.
DofetilideSulfisoxazole may increase the QTc-prolonging activities of Dofetilide.
DoxofyllineThe serum concentration of Doxofylline can be increased when it is combined with Sulfisoxazole.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Sulfisoxazole.
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Sulfisoxazole.
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Sulfisoxazole.
FelodipineThe metabolism of Felodipine can be decreased when combined with Sulfisoxazole.
FloxuridineThe metabolism of Sulfisoxazole can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Sulfisoxazole can be decreased when combined with Fluconazole.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Sulfisoxazole.
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Sulfisoxazole.
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Sulfisoxazole.
FosphenytoinThe metabolism of Fosphenytoin can be decreased when combined with Sulfisoxazole.
Fusidic AcidThe serum concentration of Sulfisoxazole can be increased when it is combined with Fusidic Acid.
GabapentinThe metabolism of Gabapentin can be decreased when combined with Sulfisoxazole.
GliclazideGliclazide may increase the hypoglycemic activities of Sulfisoxazole.
GlimepirideGlimepiride may increase the hypoglycemic activities of Sulfisoxazole.
GlipizideSulfisoxazole may increase the hypoglycemic activities of Glipizide.
GliquidoneGliquidone may increase the hypoglycemic activities of Sulfisoxazole.
GlyburideGlyburide may increase the hypoglycemic activities of Sulfisoxazole.
GoserelinGoserelin may increase the QTc-prolonging activities of Sulfisoxazole.
HexamethylenetetramineThe risk or severity of adverse effects can be increased when Hexamethylenetetramine is combined with Sulfisoxazole.
Insulin AspartInsulin Aspart may increase the hypoglycemic activities of Sulfisoxazole.
Insulin DetemirInsulin Detemir may increase the hypoglycemic activities of Sulfisoxazole.
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Sulfisoxazole.
Insulin GlulisineInsulin Glulisine may increase the hypoglycemic activities of Sulfisoxazole.
Insulin HumanInsulin Regular may increase the hypoglycemic activities of Sulfisoxazole.
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Sulfisoxazole.
IsradipineThe metabolism of Isradipine can be decreased when combined with Sulfisoxazole.
KetamineThe metabolism of Ketamine can be decreased when combined with Sulfisoxazole.
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Sulfisoxazole.
LamotrigineThe metabolism of Lamotrigine can be decreased when combined with Sulfisoxazole.
LercanidipineThe metabolism of Lercanidipine can be decreased when combined with Sulfisoxazole.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Sulfisoxazole.
LinagliptinLinagliptin may increase the hypoglycemic activities of Sulfisoxazole.
LincomycinThe therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Lincomycin.
LosartanThe metabolism of Losartan can be decreased when combined with Sulfisoxazole.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be decreased when combined with Sulfisoxazole.
MecamylamineThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Mecamylamine.
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Sulfisoxazole.
MestranolThe metabolism of Mestranol can be decreased when combined with Sulfisoxazole.
MetforminMetformin may increase the hypoglycemic activities of Sulfisoxazole.
MethotrexateThe risk or severity of adverse effects can be increased when Sulfisoxazole is combined with Methotrexate.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Sulfisoxazole.
NelfinavirThe metabolism of Sulfisoxazole can be decreased when combined with Nelfinavir.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Sulfisoxazole.
NimodipineThe metabolism of Nimodipine can be decreased when combined with Sulfisoxazole.
NisoldipineThe metabolism of Nisoldipine can be decreased when combined with Sulfisoxazole.
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Sulfisoxazole.
NorethisteroneThe metabolism of Norethindrone can be decreased when combined with Sulfisoxazole.
OctreotideOctreotide may increase the QTc-prolonging activities of Sulfisoxazole.
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Sulfisoxazole.
OxandroloneOxandrolone may increase the hypoglycemic activities of Sulfisoxazole.
ParoxetineParoxetine may increase the hypoglycemic activities of Sulfisoxazole.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Sulfisoxazole.
PhenelzinePhenelzine may increase the hypoglycemic activities of Sulfisoxazole.
PhenytoinThe metabolism of Phenytoin can be decreased when combined with Sulfisoxazole.
Picosulfuric acidThe therapeutic efficacy of Sodium picosulfate can be decreased when used in combination with Sulfisoxazole.
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Sulfisoxazole.
PrenylamineThe metabolism of Prenylamine can be decreased when combined with Sulfisoxazole.
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Sulfisoxazole.
RepaglinideRepaglinide may increase the hypoglycemic activities of Sulfisoxazole.
RifabutinThe metabolism of Rifabutin can be decreased when combined with Sulfisoxazole.
RisedronateThe metabolism of Risedronate can be decreased when combined with Sulfisoxazole.
SaquinavirThe serum concentration of Sulfisoxazole can be increased when it is combined with Saquinavir.
SaxagliptinSaxagliptin may increase the hypoglycemic activities of Sulfisoxazole.
SecobarbitalThe metabolism of Sulfisoxazole can be increased when combined with Secobarbital.
SildenafilThe metabolism of Sildenafil can be decreased when combined with Sulfisoxazole.
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Sulfisoxazole.
St. John's WortThe serum concentration of Sulfisoxazole can be decreased when it is combined with St. John's Wort.
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Sulfisoxazole.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Sulfisoxazole.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Sulfisoxazole.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Sulfisoxazole.
TesmilifeneThe serum concentration of Sulfisoxazole can be decreased when it is combined with Tesmilifene.
TestosteroneTestosterone may increase the hypoglycemic activities of Sulfisoxazole.
TheophyllineThe metabolism of Theophylline can be decreased when combined with Sulfisoxazole.
TolazamideSulfisoxazole may increase the hypoglycemic activities of Tolazamide.
TolbutamideTolbutamide may increase the hypoglycemic activities of Sulfisoxazole.
TorasemideThe metabolism of Torasemide can be decreased when combined with Sulfisoxazole.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Sulfisoxazole.
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Sulfisoxazole.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Sulfisoxazole.
VildagliptinVildagliptin may increase the hypoglycemic activities of Sulfisoxazole.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Sulfisoxazole.
VoriconazoleThe metabolism of Voriconazole can be decreased when combined with Sulfisoxazole.
WarfarinThe metabolism of Warfarin can be decreased when combined with Sulfisoxazole.
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Sulfisoxazole.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
yes
Actions
inhibitor
General Function:
Metal ion binding
Specific Function:
Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivatives.
Gene Name:
folP
Uniprot ID:
P0AC13
Molecular Weight:
30614.855 Da
References
  1. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  2. Jorgensen JH, Crawford SA, Fiebelkorn KR: Susceptibility of Neisseria meningitidis to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. J Clin Microbiol. 2005 Jul;43(7):3162-71. [PubMed:16000430 ]
  3. Fiebelkorn KR, Crawford SA, Jorgensen JH: Mutations in folP associated with elevated sulfonamide MICs for Neisseria meningitidis clinical isolates from five continents. Antimicrob Agents Chemother. 2005 Feb;49(2):536-40. [PubMed:15673729 ]
  4. Hong YL, Hossler PA, Calhoun DH, Meshnick SR: Inhibition of recombinant Pneumocystis carinii dihydropteroate synthetase by sulfa drugs. Antimicrob Agents Chemother. 1995 Aug;39(8):1756-63. [PubMed:7486915 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23